{"disease":{"id":"thromboembolism","name":"thromboembolism"},"drugs":{"marketed":[{"drug_id":"dabigatran","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran etexilate","company_name":"Generic (originally Boehringer Ingelheim)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","quality_score":69,"revenue":"1200","mechanism":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring."},{"drug_id":"xarelto","indication_name":"Prevention of venous thromboembolism from re-occuring","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Prevention of venous thromboembolism in undergoing surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fondaparinux","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arixtra","generic_name":"FONDAPARINUX","company_name":"Mylan Ireland Ltd","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":67,"revenue":null,"mechanism":"Arixtra works by blocking the action of factor Xa, a protein involved in blood clotting."},{"drug_id":"enoxaparin-sodium","indication_name":"Prevention of venous thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lovenox (Preservative Free)","generic_name":"ENOXAPARIN SODIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Low Molecular Weight Heparin","quality_score":10,"revenue":null,"mechanism":"Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting."},{"drug_id":"heparin","indication_name":"Peripheral Arterial Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Pulmonary Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"rivaroxaban","indication_name":"Prevention of venous thromboembolism from re-occuring","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"rivaroxaban","indication_name":"Prevention of venous thromboembolism in undergoing surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"dabigatran-etexilate","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"fragmin","indication_name":"Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Treatment of symptomatic venous thromboembolism to reduce recurrence in pediatric patients from birth (gestational age at least 35 weeks)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"heparin-sodium","indication_name":"Peripheral Arterial Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Pulmonary Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"warfarin","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Pulmonary Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Thromboembolism due to Prosthetic Heart Valves","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"clopidogrel","indication_name":"Peripheral Arterial Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"arixtra","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arixtra","company_name":"LifeBridge Health","drug_phase":"marketed","molecular_target":"Antithrombin-III, Coagulation factor X","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lovenox","indication_name":"Prevention of venous thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lovenox","company_name":"University of Monastir","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enoxaparin","indication_name":"Prevention of venous thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enoxaparin","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dabigatran-etexilate-de","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"}],"pipeline":[{"drug_id":"oral-anticoagulant","indication_name":"Polycythemia vera and essential thrombocythemia (thromboembolism prevention)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."}],"offLabel":[],"totalMarketed":25,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT01653405","title":"Improving Anticoagulation Control in VISN 1","phase":"NA","overall_status":"COMPLETED","enrollment_count":1260576,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT03660007","title":"Incidence of Pulmonary and Venous Thromboembolism in IVF Pregnancies After Fresh and Frozen Embryo Transfer","phase":"","overall_status":"COMPLETED","enrollment_count":902891,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04969653","title":"The Incidence of Venous Thromboembolism in Atopic Dermatitis","phase":"","overall_status":"COMPLETED","enrollment_count":754745,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT04940377","title":"Effect of the Genotype on Postoperative DVT","phase":"","overall_status":"COMPLETED","enrollment_count":502505,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04569344","title":"COVID-19 and Venous Thromboembolism Risk","phase":"","overall_status":"COMPLETED","enrollment_count":398530,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03835780","title":"The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266890,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT02828904","title":"RIVET - Retrospective Cohort Study on the Risk of Venous Thromboembolism","phase":"","overall_status":"COMPLETED","enrollment_count":124000,"lead_sponsor_name":"Center for Epidemiology and Health Research, Germany","has_results":false},{"nct_id":"NCT03799016","title":"An Observational Study on Incidence, Natural History and Treatment Patterns of Venous Thromboembolism in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":104215,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03965741","title":"Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners","phase":"","overall_status":"COMPLETED","enrollment_count":97765,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03243708","title":"Title: Randomized Trial of an EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":90537,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT03087474","title":"Treatment of Venous Thromboembolism in Real-Life Patients","phase":"","overall_status":"COMPLETED","enrollment_count":89383,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04736420","title":"Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":78605,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06020560","title":"Study of Low Molecular Weight Heparins","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":65000,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT05022563","title":"Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":55759,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05264168","title":"Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":41875,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03292666","title":"Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study","phase":"","overall_status":"COMPLETED","enrollment_count":39603,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03521908","title":"A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot","phase":"","overall_status":"COMPLETED","enrollment_count":35756,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04141228","title":"A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US","phase":"","overall_status":"COMPLETED","enrollment_count":28000,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05058521","title":"Venous thromboEmbolism Risk Profiles in Chinese hoSpitalized patiEnts (VERSE Study)","phase":"","overall_status":"COMPLETED","enrollment_count":27490,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT04444804","title":"Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":22153,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06443905","title":"Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21600,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05347550","title":"Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":21472,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT06937372","title":"Delivery and Implementation of a Randomised Crossover Trial on Thrombosis","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":21194,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05819125","title":"Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin","phase":"","overall_status":"TERMINATED","enrollment_count":21000,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT02443610","title":"Haemorrhages and Thromboembolic Venous Disease of the Postpartum","phase":"","overall_status":"COMPLETED","enrollment_count":20241,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07328152","title":"CoMbination of Data From European Cohorts as Part of the European MORPHEUS Project [HORIZON-HLTH-2022-11-01] - \"MC-MORPHEUS\".","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04736719","title":"Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":19002,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04574895","title":"Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events","phase":"NA","overall_status":"COMPLETED","enrollment_count":17427,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT06806800","title":"Venous Thromboembolism During COVID-19 Pandemic: Evaluation of the Association With the Vaccine and COVID-19 Infection","phase":"","overall_status":"COMPLETED","enrollment_count":16000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06353373","title":"Smart Technology Facilitated Venous Thromboembolism Prophylaxis Based on Bundled Evidence-based Prevention Strategies","phase":"","overall_status":"UNKNOWN","enrollment_count":15626,"lead_sponsor_name":"Navy General Hospital, Beijing","has_results":false},{"nct_id":"NCT05628207","title":"Evaluation of the SCALED (SCaling AcceptabLE cDs)","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT02943343","title":"The China Pulmonary Thromboembolism Registry Study","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05819112","title":"A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness","phase":"","overall_status":"TERMINATED","enrollment_count":14799,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05795062","title":"Treatment Patterns Among Patients With Venous Thromboembolism in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":13945,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04768036","title":"A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":10699,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT02155491","title":"Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events","phase":"","overall_status":"COMPLETED","enrollment_count":10679,"lead_sponsor_name":"Thrombosis Research Institute","has_results":false},{"nct_id":"NCT06581965","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":10078,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT03282747","title":"Distribution of Risk Factors for Venous Thromboembolism in Blood Donors","phase":"","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"Casa Sollievo della Sofferenza IRCCS","has_results":false},{"nct_id":"NCT07406074","title":"Duke Virtual IntEgrated Workflow","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06765681","title":"An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04257305","title":"Study of Venous Thromboembolism Risk Profiles and Prophylaxis in Neurosurgical Inpatients","phase":"","overall_status":"COMPLETED","enrollment_count":9010,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT06166537","title":"GRACE: Evaluating Compression Stockings in Patients That Require Extended Duration Pharmacological Thromboprophylaxis","phase":"NA","overall_status":"RECRUITING","enrollment_count":8608,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT02596230","title":"RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism","phase":"","overall_status":"COMPLETED","enrollment_count":7797,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04400877","title":"Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic","phase":"","overall_status":"COMPLETED","enrollment_count":7795,"lead_sponsor_name":"University Hospital, Linkoeping","has_results":false},{"nct_id":"NCT05643885","title":"A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":7304,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05735639","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":6660,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT03477968","title":"ThRombosis ExclUsion STudy","phase":"","overall_status":"TERMINATED","enrollment_count":5935,"lead_sponsor_name":"Diagnostica Stago","has_results":true},{"nct_id":"NCT04211181","title":"CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":5800,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05150938","title":"A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)","phase":"","overall_status":"COMPLETED","enrollment_count":5737,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04295486","title":"Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":5478,"lead_sponsor_name":"University of Miami","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}